Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials
This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bac...
Saved in:
| Published in | Antibiotics (Basel) Vol. 9; no. 3; p. 106 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
02.03.2020
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24-4.32;
= 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35-12.44;
= 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11-1.21;
= 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77-3.28;
= 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64-2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48-2.69, mortality, OR, 0.93; 95% CI, 0.09-9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. |
|---|---|
| AbstractList | This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24-4.32;
= 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35-12.44;
= 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11-1.21;
= 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77-3.28;
= 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64-2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48-2.69, mortality, OR, 0.93; 95% CI, 0.09-9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24–4.32; I2 = 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35–12.44; I2 = 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11–1.21; I2 = 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77–3.28; I2 = 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64–2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48–2.69, mortality, OR, 0.93; 95% CI, 0.09–9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24−4.32; I2 = 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35−12.44; I2 = 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11−1.21; I2 = 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77−3.28; I2 = 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64−2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48−2.69, mortality, OR, 0.93; 95% CI, 0.09−9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24-4.32; [I.sup.2] = 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35-12.44; [I.sup.2] = 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11-1.21; [I.sup.2] = 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77-3.28; [I.sup.2] = 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64-2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48-2.69, mortality, OR, 0.93; 95% CI, 0.09-9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24–4.32; I 2 = 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35–12.44; I 2 = 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11–1.21; I 2 = 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of the comparator (77.8%) (OR, 1.59; 95% CI, 0.77–3.28; I 2 = 47%). The risk of treatment-emergent adverse event (TEAE), drug-related TEAE, and all-cause mortality were similar between sitafloxacin and the comparators (TEAE, OR, 1.14; 95% CI, 0.64–2.01, drug-related TEAE, OR, 1.14; 95% CI, 0.48–2.69, mortality, OR, 0.93; 95% CI, 0.09–9.44). In conclusion, sitafloxacin is noninferior to other commonly used antibiotics with respect to both clinical and microbiological response rates in patients with an acute bacterial infection, including cUTI/APN and pneumonia. In addition, sitafloxacin is also as safe as the comparators. |
| Audience | Academic |
| Author | Chen, Yu-Hung Chen, Chao-Kun Cheng, I-Ling Lai, Chih-Cheng |
| AuthorAffiliation | 1 Department of Surgery, Chi Mei Medical Center, Tainan 73657, Taiwan; a.kun.ke@gmail.com 3 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 73657, Taiwan 2 Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan; bokey1010@gmail.com (I.-L.C.); her0windqoo@gmail.com (Y.-H.C.) |
| AuthorAffiliation_xml | – name: 3 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 73657, Taiwan – name: 2 Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan; bokey1010@gmail.com (I.-L.C.); her0windqoo@gmail.com (Y.-H.C.) – name: 1 Department of Surgery, Chi Mei Medical Center, Tainan 73657, Taiwan; a.kun.ke@gmail.com |
| Author_xml | – sequence: 1 givenname: Chao-Kun surname: Chen fullname: Chen, Chao-Kun organization: Department of Surgery, Chi Mei Medical Center, Tainan 73657, Taiwan – sequence: 2 givenname: I-Ling orcidid: 0000-0002-7420-1708 surname: Cheng fullname: Cheng, I-Ling organization: Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan – sequence: 3 givenname: Yu-Hung surname: Chen fullname: Chen, Yu-Hung organization: Department of Pharmacy, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan – sequence: 4 givenname: Chih-Cheng orcidid: 0000-0002-6334-2388 surname: Lai fullname: Lai, Chih-Cheng organization: Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 73657, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32131414$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkltrFDEUgAep2Fr7B3yQgC--rCaTy0x8ELal6kJFsOtzOLlts8wmNZMV10d_uZlura2GQA7Jd74kh_O0OYgpuqZ5TvBrSiV-A7EEHVIJZpSYYoLFo-aoxZ2cCdq3B_fiw-ZkHNe4Dkloj_snzSFtCSWMsKPm17n3wYDZIYgWXYJ3ZYeSR5ehgB_SDzAhojrLlUPL7KBsXCwTMDfb4tApmOJygAEtonemhBTfojn65ArMIMKwG8M40V-qPW3CT2fRWYolp2Go4XLKHJ81j31d3Mntetx8fX--PPs4u_j8YXE2v5gZ3rIyg7bvOXANnlhNJNZAiNeEWiPBddILhiWWmvXMEpDcOWlk57VhRrQgOKfHzWLvtQnW6jqHDeSdShDUzUbKKwW51nNwSpqW9ZSB57JnlFvQllgJ0mvJrdC2ut7tXddbvXHW1KJkGB5IH57EcKVW6bvqSH2gYFXw6laQ07etG4vahNG4YYDo0nZULe1Iz7nAoqIv_0HXaZtrcW-olgnBCP5LraB-IESf6r1mkqq5aDsqCaET1e4pk9M4ZufvnkywmvpK_d9XNenF_c_epfzpIvobwPfOYA |
| CitedBy_id | crossref_primary_10_1093_jac_dkad208 crossref_primary_10_3390_pharmaceutics15030804 crossref_primary_10_3390_pharmaceutics13081289 crossref_primary_10_1111_1758_2229_13243 crossref_primary_10_3390_pharmaceutics15112554 crossref_primary_10_3389_fmicb_2021_622275 crossref_primary_10_1093_jac_dkac365 crossref_primary_10_3389_fphar_2021_680178 crossref_primary_10_3390_pharmaceutics14081749 |
| Cites_doi | 10.1016/S0924-8579(00)00344-7 10.1136/bmj.d5928 10.1016/j.jiac.2013.08.004 10.1016/j.jmii.2014.02.002 10.1007/s10156-012-0514-4 10.1016/j.jiac.2017.05.005 10.2165/11207380-000000000-00000 10.2147/IDR.S178183 10.1016/j.jiac.2019.03.008 10.1016/j.jiac.2019.04.019 10.1093/jac/46.4.633 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 MDPI AG 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 by the authors. 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 MDPI AG – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 by the authors. 2020 |
| DBID | NPM AAYXX CITATION 7QL 7T7 8FD 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 GNUQQ HCIFZ LK8 M7P P64 PIMPY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.3390/antibiotics9030106 |
| DatabaseName | PubMed CrossRef Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Biological Science Collection Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest One Academic MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2079-6382 |
| ExternalDocumentID | oai_doaj_org_article_9c24834af598435dabd1d9a9fb95d6bd A627391130 10_3390_antibiotics9030106 32131414 |
| Genre | Journal Article |
| GeographicLocations | Japan Taiwan |
| GeographicLocations_xml | – name: Taiwan – name: Japan |
| GroupedDBID | 53G 5VS 8FE 8FH AADQD AAFWJ AAHBH ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI CCPQU ECGQY GROUPED_DOAJ HCIFZ HYE IAO KQ8 LK8 M48 M7P MODMG M~E NPM OK1 PGMZT PIMPY PROAC RPM AAYXX CITATION AFPKN ITC 7QL 7T7 8FD ABUWG AZQEC C1K DWQXO FR3 GNUQQ P64 PQEST PQQKQ PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c524t-a2885a5baf1db190ba11fb13dc9ae79f640909b484d1a95ee9c97fbc4c62a6553 |
| IEDL.DBID | RPM |
| ISSN | 2079-6382 |
| IngestDate | Tue Oct 22 15:14:42 EDT 2024 Tue Sep 17 21:03:37 EDT 2024 Thu Oct 24 21:19:44 EDT 2024 Thu Oct 10 22:10:17 EDT 2024 Thu Feb 22 23:56:10 EST 2024 Tue Oct 29 02:58:00 EDT 2024 Wed Oct 16 00:46:11 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | acute pyelonephritis sitafloxacin acute bacterial infection pneumonia complicated urinary tract infection |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c524t-a2885a5baf1db190ba11fb13dc9ae79f640909b484d1a95ee9c97fbc4c62a6553 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The two authors contributed equally. |
| ORCID | 0000-0002-7420-1708 0000-0002-6334-2388 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148464/ |
| PMID | 32131414 |
| PQID | 2372466410 |
| PQPubID | 2032437 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9c24834af598435dabd1d9a9fb95d6bd pubmedcentral_primary_oai_pubmedcentral_nih_gov_7148464 proquest_miscellaneous_2371855606 proquest_journals_2372466410 gale_infotracmisc_A627391130 crossref_primary_10_3390_antibiotics9030106 pubmed_primary_32131414 |
| PublicationCentury | 2000 |
| PublicationDate | 20200302 |
| PublicationDateYYYYMMDD | 2020-03-02 |
| PublicationDate_xml | – month: 3 year: 2020 text: 20200302 day: 2 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Antibiotics (Basel) |
| PublicationTitleAlternate | Antibiotics (Basel) |
| PublicationYear | 2020 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Amano (ref_2) 2013; 66 Higgins (ref_12) 2011; 343 Tateda (ref_13) 2019; 25 Miyazaki (ref_9) 2019; 25 Lojanapiwat (ref_7) 2019; 12 Feldman (ref_5) 2001; 17 Nakamura (ref_15) 2014; 20 Malaisri (ref_8) 2017; 23 Yamaguchi (ref_16) 2006; 59 Fujita (ref_6) 2013; 19 Kawada (ref_11) 2008; 56 Keating (ref_1) 2011; 71 Dong (ref_14) 2015; 8 Amano (ref_3) 2016; 69 Shetty (ref_10) 2000; 46 Huang (ref_4) 2015; 48 |
| References_xml | – volume: 17 start-page: 177 year: 2001 ident: ref_5 article-title: An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia publication-title: Int. J. Antimicrob. Agents doi: 10.1016/S0924-8579(00)00344-7 contributor: fullname: Feldman – volume: 343 start-page: d5928 year: 2011 ident: ref_12 article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials publication-title: BMJ doi: 10.1136/bmj.d5928 contributor: fullname: Higgins – volume: 20 start-page: 48 year: 2014 ident: ref_15 article-title: Susceptibility of various oral antibacterial agents against extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae publication-title: J. Infect. Chemother. doi: 10.1016/j.jiac.2013.08.004 contributor: fullname: Nakamura – volume: 59 start-page: 428 year: 2006 ident: ref_16 article-title: In-vitro susceptibilites to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004 publication-title: Jpn. J. Antibiot. contributor: fullname: Yamaguchi – volume: 48 start-page: 545 year: 2015 ident: ref_4 article-title: Comparative in vitro activity of sitafloxacin against bacteremic isolates of carbapenem resistant Acinetobacter baumannii complex publication-title: J. Microbiol. Immunol. Infect. doi: 10.1016/j.jmii.2014.02.002 contributor: fullname: Huang – volume: 8 start-page: 8135 year: 2015 ident: ref_14 article-title: In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii publication-title: Int. J. Clin. Exp. Med. contributor: fullname: Dong – volume: 19 start-page: 472 year: 2013 ident: ref_6 article-title: Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: Nested cohort within a multicenter clinical trial publication-title: J. Infect. Chemother. doi: 10.1007/s10156-012-0514-4 contributor: fullname: Fujita – volume: 23 start-page: 556 year: 2017 ident: ref_8 article-title: A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A pilot study publication-title: J. Infect. Chemother. doi: 10.1016/j.jiac.2017.05.005 contributor: fullname: Malaisri – volume: 71 start-page: 731 year: 2011 ident: ref_1 article-title: Sitafloxacin: In bacterial infections publication-title: Drugs doi: 10.2165/11207380-000000000-00000 contributor: fullname: Keating – volume: 12 start-page: 173 year: 2019 ident: ref_7 article-title: Oral sitafloxacin vs. intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: A randomized controlled trial publication-title: Infect. Drug Resist. doi: 10.2147/IDR.S178183 contributor: fullname: Lojanapiwat – volume: 25 start-page: 594 year: 2019 ident: ref_13 article-title: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2016 publication-title: J. Infect. Chemother. doi: 10.1016/j.jiac.2019.03.008 contributor: fullname: Tateda – volume: 25 start-page: 886 year: 2019 ident: ref_9 article-title: The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial publication-title: J. Infect. Chemother. doi: 10.1016/j.jiac.2019.04.019 contributor: fullname: Miyazaki – volume: 69 start-page: 131 year: 2016 ident: ref_3 article-title: In vitro activity of sitafloxacin against atypical bacteria (2009–2014) and comparison between susceptibility of clinical isolates in 2009 and 2012 publication-title: Jpn. J. Antibiot. contributor: fullname: Amano – volume: 56 start-page: 81 year: 2008 ident: ref_11 article-title: Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections publication-title: Jpn. J. Chemother. contributor: fullname: Kawada – volume: 46 start-page: 633 year: 2000 ident: ref_10 article-title: Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/46.4.633 contributor: fullname: Shetty – volume: 66 start-page: 311 year: 2013 ident: ref_2 article-title: In vitro activity of sitafloxacin against clinical isolates in 2012 publication-title: Jpn. J. Antibiot. contributor: fullname: Amano |
| SSID | ssj0000913808 |
| Score | 2.2209475 |
| Snippet | This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 106 |
| SubjectTerms | acute bacterial infection acute pyelonephritis Antibiotics Bacteria Bacterial diseases Bacterial infections Bias Clinical trials Comparators complicated urinary tract infection Dosage and administration Fluoroquinolones Infections Medical research Meta-analysis Mortality Pathogens Patients Pneumonia Population Pyelonephritis Randomization Response rates Safety Sensitivity analysis sitafloxacin Software reviews Streptococcus infections Studies Urinary tract Urinary tract diseases Urinary tract infections Urogenital system |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF-kT76I355WWUH6YkNvsx_J-nYtLVWoFHuFvoXZLwxoIjYHvT76lzuT5K539MEXIYSQnSSzmZmdmWX2t4x9MIV3UUqVaYMnFRNkAMZlpfOYPjjjZU6Lk8--mtNL9eVKX21s9UU1YQM88PDjDqzPab4LkrYluvYALohgwSZndTAu9KPv1G4kU_0YbIUsp-WwSkZiXn-AfNaubgn72FIaQFscbXiiHrD__rC84Ze2ayY3nNDJY_ZojB75bOD6CXsQm6ds73yAn17u8_ndaqrrfb7Hz--AqZfP2J9jwotAQg5N4BeQYrfkbeIXNe3h296ArxuOB8aEfL4qQCeCmV90kR8OwM74_c9jBVfzic_4Wezwz4_YJkT9Dd_e_qxvY-BHQyH8D7yc95r-nF2eHM-PTrNxD4bM61x1GeRlqUE7SCI4DB4cCJGckMFbiIVNBvPDqXWqVEGA1TFab4uEgvYmB6O1fMF2mraJrxjPpQfQ4BKBfEmVwAdVgMGEySlrgpqwjyt5VL8GqI0KUxSSXnVfehN2SCJbUxJMdn8Dlacalaf6l_JM2C4JvCJjRql6NC1fzQyGdOgD5BSbV4pQjaZ9XeWyyAmTX2Dz-3UzPUnlak1sFz0NxkEYTCKbLwe9WTMqcyGFEtjdYkujtnqy3dLU33vg7wJzV2XU6__R9TfsYU5TB1ROl--yne73Ir7F-Kpz73pT-gtk9ii0 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdb-rKXse9l64YGoy-rqS3JsrWXkZSUbtAS2hT6ZvTZGTa7axxY9ri_fHe280VhEEyIzonM7066u5x-R8hHmVnjORdRKuEifNCR1tJEubEQPhhpOcPDyWfn8vRKfLtOr_uE27wvq1ytie1C7WqLOfIjxjOGVOhJ_OX2V4Rdo_Df1b6FxkOyxyBSiAdkbzw5n16ssyzIepnHeXdahkN8fwTzLU1ZIweywnAAWx1t7Ugtcf_95Xlrf9qtndzajE6ekMe9F0lHHexPyQNfPSMH046GenlIZ5tTVfNDekCnG4Lq5XPyd4K8ESBIdeXopQ6-WdI60MsSe_nWv7UtKwov8A3pbFWIjgIju2g8HXcEz_D7X_tKruozHdEz3wACPccJSl_At9c_yz_e0eOuIP4HvJ21Gv-CXJ1MZsenUd-LIbIpE02kWZ6nOjU6JM6AE2F0kgSTcGeV9pkKEuLEWBmRC5dolXqvrMoCAG4l0zJN-UsyqOrKvyaUcat1qk1Asi8ugrZOZFpC4GSEkk4MyacVHsVtR7lRQKiC6BX30RuSMUK2lkS67PaD-u6m6K2vUJZh0lSHVOXgHzptXOKUVsGo1EnjhmQfAS_QqAFVCyZmi5EE1w72Ah7D8EoRit7E58VGIYfkw3oY78SytcrXi1YG_CFwKmGarzq9WU-Us4QnIoHHzXY0audJdkeq8ntLAJ5BDCukePP_ab0ljxgmB7Bgju2TQXO38O_Ag2rM-95M_gHeyiCE priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF9KffFF_LZaZQXpi43efiYriFxLSxUqxd5B38J-aqAmes1Bz0f_cmeS3LVH9UE4juN2LrfJzGR_vzD7G0Je6dy7KITMlIY3GZPNrNUuK5wH-uC0Fxw3Jx9_1kdT-elMnW2QZbuj4QJe_JXaYT-p6ez8zeXPxQdI-PfIOIGyv4UpVK5qUNbYIMJHBe5bXAJTx1K-Ae53d2bDRNE3qRvlJoPQ4_0-mn8cZm2t6iT9b964r61c61WV15apw7vkzoAv6bgPiHtkI9b3yc5JL1C92KWTq_1WF7t0h55cSVcvHpDfB6goAYbU1oGe2hTbBW0SPa2wy29zaX1VU3gBaqSTZYk6Goz9vI10r5d-hv__ONR41e_omB7HFnwzqJ-g9Rc4evO9-hUD3e9L5c_h46TLhYdkengw2T_Khi4NmVdctpnlRaGscjax4ABeOMtYckwEb2zMTdLAIEfGyUIGZo2K0XiTJwgFr7nVSolHZLNu6viEUC68tcq6hDJgQibrg8ytBkrlpNFBbpHXS3-UP3oxjhJIDHqvvOm9LbKHLltZopB290Uz-1oOeVkaz_Fxqk3KFIAcg3WBBWNNckYF7cIW2UaHlxiA4FUPyefLsQbQB6uEGMHwMhDKZeyWXOQcVfsZDL9cDeMvsaCtjs28swGkBHATpvm4j5vVRAVngkkGp5uvRdTamayP1NW3Tho8B3YrtXz6XxfqGbnN8SkCVtbxbbLZzubxOUCt1r3o8ucPD1Ar3w priority: 102 providerName: Scholars Portal |
| Title | Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32131414 https://www.proquest.com/docview/2372466410 https://search.proquest.com/docview/2371855606 https://pubmed.ncbi.nlm.nih.gov/PMC7148464 https://doaj.org/article/9c24834af598435dabd1d9a9fb95d6bd |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6S9NJL6btuU7OFkkuj2PuUtjfbOKQFB5M4kJvYl1JBLIVEhrrH_vLO6uHY5FYwwnhH8kozo_1m-fZbhL7K2BrPGI-EhAP3mY60liZKjIXywUjLaFicPDuXZ1f857W43kOiWwtTk_atyU-K2-VJkf-quZV3SzvoeGKD-WwSA4bnkg_20T4E6FaJXr9-FWHJMGkWyDAo6QfQxdzkZZA9VqECGIZ9ixgljHDCd8ajWrb_6ct5a3TaZU5uDUWnL9GLFkPiUdPXV2jPF6_R0bwRoV4f48XjmqqHY3yE54_y1Os36O80qEaAIdaFw5c689Ualxm-zMNOvuVvbfMCwweQIV50NPRgMLKryuNxI-8M__-j5XEV3_EIz3wFz79VOAnWF3D1cpn_8Q5PGjr8LXxd1PH-Fl2dTheTs6jdiSGygvIq0jRJhBZGZ8QZgBBGE5IZwpxV2scqk1AlDpUBrziilfBeWRVn4G4rqZZCsHfooCgL_wFhyqzWQpssSH0xnmnreKwllE2GK-l4D33r_JHeNYIbKRQqwZHpU0f20Di4bGMZxLLrH8r7m7QNmVRZGqZMdSZUAujQaeOIU1plRgknjeuhw-DwNKQ0eNVCgtl0JAHYwUjAhtDcBULaJvhDSllMgzI_geYvm-ZwZiCtFb5c1TaAhgBSQjffN3Gz6WgXfj0U70TUzp3stkA21PLfbfR__O8zP6HnNMwaBCYdPUQH1f3KfwZoVZk-ejaens8v-vXUBBxnPOnX6fUPIz4riw |
| link.rule.ids | 230,315,730,783,787,867,888,2109,2228,21400,24330,27936,27937,33756,33757,43817,53804,53806,74630 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9tAEF7a5NBeSt9xmrZbKLk0IpZ2tdL2Uuzg4LSxMYkDuYl9toJGSmMZ6h77yzsjyS8CBSOMd2Sv-GZ2Z8az3xDyUSRGO8Z4EAu4cOdVoJTQQaoNhA9aGBbh4eTRWAyv-Nfr-LpNuM3assrlmlgv1LY0mCM_jlgSIRV62P1y-yvArlH472rbQuMh2UWqKgi-dvuD8eRilWVB1su0mzanZRjE98cw31znJXIgSwwHsNXRxo5UE_ffX5439qft2smNzej0KXnSepG018D-jDxwxXNyOGloqBdHdLo-VTU7ood0siaoXrwgfwfIGwGCVBWWXirvqgUtPb3MsZdv-VuZvKDwAt-QTpeF6CjQM_PK0X5D8Ay_f9ZWchWfaY-OXAUItBwnKH0B317e5H-cpSdNQfxPeDutNf4luTodTE-GQduLITBxxKtARWkaq1grH1oNToRWYeh1yKyRyiXSC4gTu1LzlNtQydg5aWTiAXAjIiXimL0iO0VZuD1CI2aUipX2SPbFuFfG8kQJCJw0l8LyDvm0xCO7bSg3MghVEL3sPnod0kfIVpJIl11_UN59z1rry6SJMGmqfCxT8A-t0ja0UkmvZWyFth1ygIBnaNSAqgETM1lPgGsHewHrwvBSEbLWxGfZWiE75MNqGO_EsrXClfNaBvwhcCphmq8bvVlNlEUhC3kIj5tsadTWk2yPFPmPmgA8gRiWC77__2m9J4-G09F5dn42_vaGPI4wUYDFc9EB2anu5u4teFOVfteazD-4jSN- |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegkxAviO8VBhgJ7YVFbWLHiXlB7Wi1AauqrZP2FvkTIkEy1lSiPPKXc5ekX5qEFEVRfWlt3Z195_78O0LeicRoxxgPYgE37rwKlBI6SLWB9EELwyI8nHw2ESeX_PNVfNXin-YtrHI1J9YTtS0N7pH3IpZESIUe9nu-hUVMP40_Xv8KsIIU_tPaltO4S_YSLli_Q_aGo8n0fL3jggyYaT9tTs4wyPV70Pdc5yXyIUtMDbDs0dbqVJP4356qt9aqXRzl1sI0fkgetBElHTQm8IjcccVjcjhtKKmXR3S2OWE1P6KHdLohq14-IX9HyCEBglQVll4o76olLT29yLGub_lbmbygcEGcSGcrUDoKDMyicnTYkD3D75-2qK7iAx3QM1eBNlq-E5Q-h28vf-Z_nKXHDTj-BzzOaut_Si7Ho9nxSdDWZQhMHPEqUFGaxirWyodWQ0ChVRh6HTJrpHKJ9AJyxr7UPOU2VDJ2ThqZeFC-EZESccyekU5RFm6f0IgZpWKlPRJ_Me6VsTxRApIozaWwvEver_SRXTf0GxmkLai97Lb2umSIKltLInV2_UF58y1rPTGTJsINVOVjmUKsaJW2oZVKei1jK7TtkgNUeIYODlo14G4mGwgI82BdYH1oXhlC1rr7PNsYZ5e8XTfjmwhhK1y5qGUgNoIAE7r5vLGbdUdZFLKQhzDcZMeidkay21Lk32sy8ATyWS74i_936w25B96SfT2dfHlJ7ke4Z4A4uuiAdKqbhXsFgVWlX7ce8w8dHies |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+Safety+of+Sitafloxacin+in+the+Treatment+of+Acute+Bacterial+Infection%3A+A+Meta-analysis+of+Randomized+Controlled+Trials&rft.jtitle=Antibiotics+%28Basel%29&rft.au=Chen%2C+Chao-Kun&rft.au=Cheng%2C+I-Ling&rft.au=Chen%2C+Yu-Hung&rft.au=Lai%2C+Chih-Cheng&rft.date=2020-03-02&rft.issn=2079-6382&rft.eissn=2079-6382&rft.volume=9&rft.issue=3&rft.spage=106&rft_id=info:doi/10.3390%2Fantibiotics9030106&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_antibiotics9030106 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2079-6382&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2079-6382&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2079-6382&client=summon |